Research Articles Library
Literature Analysis Tools
Advanced Search
Filter by PMID, year, source, DOI and other criteria
Literature Analysis
Analyze research trends and hotspots
Batch Export
Export search results to Excel/PDF
Post-marketing surveillance of tofacitinib in patients with ulcerative colitis in Japan: a final report of safety and effectiveness data
Publication Year: 2025 Source: J Gastroenterol PMID: 40259041
BACKGROUND: We present the final analysis of a tofacitinib post-marketing surveillance (PMS) study in Japanese patients with ulcerative colitis (UC). METHODS: Safety/effectiveness data were evaluated (through Sept/30/2022). All patients with UC in Japan receiving tofacitinib were registered (60-week observation period). Adverse events (AEs) were recorded. Per protocol, several AEs were …
Clinical Outcome of Inflammatory Bowel Disease with Clostridioides difficile Polymerase Chain Reaction Toxin-Positive/Enzyme Immunoassay Toxin-Negative: A Retrospective Cohort Study
Publication Year: 2025 Source: Dig Dis Sci PMID: 40259149 DOI: 10.1007/s10620-025-09045-4
BACKGROUND: Clostridioides difficile infection (CDI) frequently occurs concurrently in patients with inflammatory bowel disease (IBD), and differential diagnosis from IBD flares is critical. However, clinical management of C. difficile in IBD patients with polymerase chain reaction toxin-positive (tPCR+)/enzyme immunoassay toxin-negative (tEIA-) results has not yet been investigated. AIMS: We aimed …
The role of squamous cell carcinoma antigen and cytokeratin 19 fragment in predicting the outcome of esophageal cancer patients: insights from a meta-analysis
Publication Year: 2025 Source: World J Surg Oncol PMID: 40259318
BACKGROUND: The accurate prognostication and recurrence monitoring of esophageal cancer (EC) are pivotal yet challenging. Despite the promising roles of squamous cell carcinoma antigen (SCC) and cytokeratin 19 fragment (CK19 Fragment) as cancer biomarkers in EC, their prognostic value remains unquantified. This meta-analysis is the first to quantitatively assess the …
Improvement of the inflammation-damaged intestinal barrier and modulation of the gut microbiota in ulcerative colitis after FMT in the SHIME® model
Publication Year: 2025 Source: BMC Complement Med Ther PMID: 40259351
BACKGROUND: Fecal microbiota transplantation (FMT) seems to be a promising approach in ulcerative colitis (UC) management with the aim of repopulating a patient's dysbiotic microbiota with beneficial bacteria and restore its metabolic activity to its healthy characteristics. Metabolites present after FMT may improve the function and integrity of the intestinal …
Balancing Promise and Uncertainty: PPAR Agonists in IBD Therapy
Publication Year: 2025 Source: J Gastroenterol Hepatol PMID: 40259682 DOI: 10.1111/jgh.16978
PPARgamma/beta/delta agonists have emerged as potential therapeutic agents for inflammatory bowel disease (IBD) due to their immunomodulatory effects and ability to influence gut microbiota composition. Li et al. investigated their impact on dextran sodium sulfate (DSS)-induced colitis, demonstrating reduced colonic inflammation and favorable microbiota shifts. However, methodological considerations, including the …
Oral Fusobacterium nucleatum exacerbates ulcerative colitis via the oral-gut axis: mechanisms and therapeutic implications
Publication Year: 2025 Source: Front Cell Infect Microbiol PMID: 40260115
BACKGROUND: Fusobacterium nucleatum (F. nucleatum) is an anaerobic bacterium known for its association with periodontal disease and oral infections. It has been implicated in the development of gastrointestinal diseases such as inflammatory bowel disease and colorectal cancer. Ulcerative colitis (UC), which is characterized by chronic inflammation of the colon, is …
Racial Disparities in Utilization of Medications and Disease Outcomes in Inflammatory Bowel Disease Patients
Publication Year: 2025 Source: Crohns Colitis 360 PMID: 40260307 DOI: 10.1093/crocol/otaf021
BACKGROUND: Although traditionally associated with White European ancestry, inflammatory bowel disease (IBD) has increased among different races and ethnicities. Large studies conducted in the United States and Canada have identified more complex disease phenotypes among Black patients. Our study aimed to investigate disparities in IBD treatments and outcomes between Black …
Efficacy and Safety of Mirikizumab in the Treatment of Moderately to Severely Active Ulcerative Colitis Regardless of Baseline Modified Mayo Score: Results From the Phase 3 LUCENT Trials
Publication Year: 2025 Source: Crohns Colitis 360 PMID: 40260308
BACKGROUND: The modified Mayo score (mMS) is a measure for ulcerative colitis (UC) disease activity. Recent US Food and Drug Administration guidance for moderately to severely active UC trials suggests that patients should have baseline mMS of 5-9 including an endoscopy score of at least 2, as opposed to the …
SIAE-Mediated Loss of Sialic Acid Acetylation Contributes to Ulcerative Colitis
Publication Year: 2025 Source: J Inflamm Res PMID: 40260449
BACKGROUND: Ulcerative colitis (UC) disrupts the colon's protective mucus layer, exposing the epithelium to bacteria and triggering inflammation. This barrier, crucial for intestinal health, depends on complex glycosylation, notably sialic acid modifications. However, the precise role of sialic acid acetylation and the enzyme SIAE (sialic acid acetylesterase) in UC pathogenesis …
More Than Meets the Eye: Interpreting Results of a Negative Trial
Publication Year: 2025 Source: Clin Infect Dis PMID: 40260545 DOI: 10.1093/cid/ciaf139
No Abstract
Need more literature?
The current database contains 98453 research articles. If you need to search for more literature or perform AI analysis, please use our knowledge acquisition module or explore external literature resources.
External Resources: Access comprehensive literature databases worldwide